SEC Form 4 · accession 0001209191-18-014727
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Dec 13, 2017
Accepted (ET)
Feb 28, 2018 · 7:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2017 | A | 5 | $20.47 | A | 12,505 | D | |
| Common StockF1 | holding | — | — | — | 2,802,638 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $22.16 | Feb 26, 2018 | A | 300,000 | A | — | Feb 25, 2028 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F225% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter.